

BioDuro-Sundia and X-Chem focus on new small molecule drug discovery in China

08 August 2022 | News

Partnership to launch DNA Encoded Compound Library services



BioDuro-Sundia, an industry-leading drug discovery, development and commercial service contract research development and manufacturing organisation (CRDMO) backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, have jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs.

X-Chem will leverage its powerful DEL technology platform and large collection of novel, diverse lead- and drug-like small molecule compounds to help customers significantly accelerate the discovery of hits and expand their target range.

Combined with BioDuro-Sundia's one-stop drug discovery platform, customers can access world-class discovery technologies and support, covering hit identification and optimization, evaluation of lead and candidate compounds, and quickly advance to preclinical development.

As a pioneer in DEL technology, X-Chem's libraries contain over 250 billion small molecules. X-Chem has licensed more than 100 research projects to companies in the US, Europe and Japan, comprising over three hundred independent chemical series and more than one thousand validated hit compounds.

BioDuro-Sundia will utilize its powerful protein screening platform to assist customers to complete the protein qualification, ensuring that its purity, concentration and degree of aggregation meet the requirements for compound library screening to ensure the best chances for hit identification.